Drug GMP Report
February 2010
Expert: Form 483 Responses Must Detail Resolutions
Drugmakers should not respond with a single comprehensive plan to a Form 483 with multiple observations, an expert says.
This article is viewable by subscribers only. To view this article, please select an option below.
|